Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based RXi Pharmaceuticals and MirImmune have entered into an exclusive license agreement to use RXi's new sd-rxRNA technology in developing new cell-based cancer immunotherapies.
Subscribe to our email newsletter
According to the companies, the deal has the potential to result in new patient friendly cancer treatments that could be a significant step towards personalized medicine.
As part of the deal, MirImmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products.
By using the sd-rxRNA technology, MirImmune will develop cell-based therapeutics to target immune inhibitory pathways which are responsible for limiting the efficacy of cancer immunotherapies.
RXi Pharmaceuticals president and CEO Dr Geert Cauwenbergh said: "This license agreement marks the latest milestone for the company to partner and collaborate with industry to provide new and innovative therapeutics, while also providing the potential for a long-term financial return for our shareholders."
Under the terms of the deal, MirImmune will gain access to RXi’s sd-rxRNA and rxRNAori patent families for ex vivo modification of cells for the treatment of cancer.
RXi’s patents include the composition of the sd-rxRNA and rxRNAori RNAi structures, as well as potential targets for cell-based therapeutics.
In return, RXi is eligible to receive an annual licensing fee, clinical milestone payments, sublicensing income and single digit royalties.
Pending achievement of few MirImmune’s gating milestones, RXi will have the right to acquire a double-digit equity stake in MirImmune.